심방세동환자에 있어 고주파전극도자술 시 와파린 용량변화
Warfarin Maintenance Dosing patterns in patients undergoing RFA for atrial fibrillation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Radiofrequency ablation (RFA) is an effective strategy for the treatment of drugrefractory atrial fibrillation (AF). Our department evaluated warfarin maintenance dose on peri procedure in patients with AF, who underwent RFA, and analyzed factors that affected International normalized ratio (INR) to obtained factors, which are applicable in ACS (anticoagulant service). A total of 84 patients were enrolled, who underwent the RFA and were followed up at cardiological outpatient department from January 2009 to June 2010. Of those 84 patients, only 37 patients maintained target INR* in survey period. They were treated with warfarin during ablation and visited at ACS regularly. This study is based on ACS counsel record and EMR, retrospectively. Investigated characteristics are age, gender, smoking, drinking, the number of RFA, comorbidities, and the mean total weekly dose (TWD), during the period of attained target INR and mean value of INR in pre- and post-ablation. The mean TWD of the 37 patients were 28.1 mg (±0.98) pre-ablation and 24.9mg(±0.83) postablation,which decreased 12.0% compared to that of pre-ablation (p<0.001). Factors like age, gender, hypertension, and early adverse effect, didn`t affect the degree of warfarin dose reduc-tion between pre- and post RFA. However, TWD differed significantly, according to the maintenance dosage change on peri-procedure between the diabetic group and the non-diabetic group (p=0.05). TWD of non-diabetics decreased during the procedure (28.5±1.07→24.8±0.91, p<0.001), and TWD of diabetics did not differ significantly, during the procedure (p=1.0). Based on this study, it’s possible for patients after RFA to be treated with lower dose warfarin. But further clinical trials are needed to customize the degree of warfarin dose reduction. Diabetics can maintain the same dosage of warfarin compared with beforehand, but it needs confirmed results through large study. Target INR*: 2.0~3.0(±0.2)
Abstract
Radiofrequency ablation (RFA) is an effective strategy for the treatment of drugrefractory atrial fibrillation (AF). Our department evaluated warfarin maintenance dose on peri procedure in patients with AF, who underwent RFA, and analyzed factors that affected International normalized ratio (INR) to obtained factors, which are applicable in ACS (anticoagulant service). A total of 84 patients were enrolled, who underwent the RFA and were followed up at cardiological outpatient department from January 2009 to June 2010. Of those 84 patients, only 37 patients maintained target INR* in survey period. They were treated with warfarin during ablation and visited at ACS regularly. This study is based on ACS counsel record and EMR, retrospectively. Investigated characteristics are age, gender, smoking, drinking, the number of RFA, comorbidities, and the mean total weekly dose (TWD), during the period of attained target INR and mean value of INR in pre- and post-ablation. The mean TWD of the 37 patients were 28.1 mg (±0.98) pre-ablation and 24.9mg(±0.83) postablation,which decreased 12.0% compared to that of pre-ablation (p<0.001). Factors like age, gender, hypertension, and early adverse effect, didn`t affect the degree of warfarin dose reduc-tion between pre- and post RFA. However, TWD differed significantly, according to the maintenance dosage change on peri-procedure between the diabetic group and the non-diabetic group (p=0.05). TWD of non-diabetics decreased during the procedure (28.5±1.07→24.8±0.91, p<0.001), and TWD of diabetics did not differ significantly, during the procedure (p=1.0). Based on this study, it’s possible for patients after RFA to be treated with lower dose warfarin. But further clinical trials are needed to customize the degree of warfarin dose reduction. Diabetics can maintain the same dosage of warfarin compared with beforehand, but it needs confirmed results through large study. Target INR*: 2.0~3.0(±0.2)
참고문헌 (12)
- Giovannii B.F, "Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2:results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy", Journal of cardiovascular electrophysiology, 20, pp.22~28 (2009)
- Luigi D.B, "Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation", Circulation, 121, pp.2550~2556 (2010)
- Sara R.V, "Periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation", Thrombosis research, 126, pp.69~77 (2010)
- Viles-Gonzalez J.F, "risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation", Current cardiology reports, 13, pp.38~42 (2010)
- Jack A, "The pharmacology and management of the vitamin K antagonists _ the seventh ACCP conference on antithrombotic and thrombolytic therapy", Chest, 126, pp.204~233 (2004)
- 권효정, "심방세동 환자의 연령별 와파린 초기용량 적정성 평가 및 새로운 용량조절 기준설정", 병원약사회지, 25(2), pp.1~10 (2008), 한국병원약사회
- David G, "Warfarin Maintenance Dosing patterns in clinical practice", Chest, 127, pp.2049~2056 (2005)
- 남주연, "Warfarin 복용 고령 환자의 출혈 현황 및 위험성 예측", 병원약사회지, 27(3), pp.281~292 (2010), 한국병원약사회
- Rebecca J.B, "A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin", Annals of internal medicine, 133(9), pp.687~695 (2000)
- Beijers H.J, "Impaired glucose metabolism and type 2 diabetes are associated with hypercoagulability - potential role of central adiposity and low-grade inflammation - The Hoorn Study", Thrombosis research, pp.417~458 (2011)
- David G, "Warfarin maintenance dosing patterns in clinical practice _implications for safer anticoagulation in the elderly population", ACCP Chest, 127(6), pp.2049~2056 (2005)
- Gregory Y.H, "Comparative validation of a Nevel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation", JACC, 57(2), pp.173~180 (2011)